The Unique Challenges of Living with a Rare Disease

Living with a rare disease comes with a unique set of challenges. By definition, a rare disease affects fewer than one in 2,000 individuals, but collectively, there are several thousand different rare diseases impacting millions of people worldwide. Despite this large community, patients often feel isolated due to the low number of cases for each specific condition. Many face long and difficult diagnostic journeys, limited treatment options, and a lack of understanding from both healthcare professionals and society.

Beyond medical challenges, rare diseases take an immense emotional and psychological toll. The uncertainty surrounding these conditions, coupled with the difficulty of finding others who truly understand, can lead to increased levels of stress, anxiety, and depression. Research shows that individuals with rare diseases frequently experience higher rates of mental health struggles than the general population. However, while psychosocial support is a critical component of comprehensive care, it is largely unavailable for this patient group.

There are several reasons for this gap in care. Traditional support programs, designed for more common chronic conditions like diabetes or COPD, do not always address the unique struggles faced by those with rare diseases. The small and geographically dispersed patient populations make disease-specific support programs difficult to implement. As a result, patients with rare diseases are often left without the crucial emotional and psychological assistance they need.

A New Approach to Psychosocial Support: The Q.RARE.LI Program

Recognizing this gap, our team at the University Medical Center Hamburg-Eppendorf in Germany developed a structured, peer-delivered psychosocial support program tailored specifically for individuals with rare diseases. This program is designed to be transdiagnostic, meaning it is not limited to a single disease but instead focuses on common challenges shared by patients with different conditions. Additionally, it is location-independent, making it accessible to patients regardless of where they live.

The program consists of two main components: a six-week self-help manual based on Acceptance and Commitment Therapy (ACT) and peer-support. The manual covers crucial topics such as coping with emotions, accepting the disease, identifying personal values, and setting meaningful life goals. Each week, participants complete one chapter and additionally receive a 30-minute telephone session with a peer-counsellor, allowing them to reflect on the content with someone who shares their lived experience.

Peer-counselors, who are also individuals with rare diseases, undergo a two-day training program, which prepares them to guide these discussions. They are provided with consultation guidelines and receive supervision from psychologists or psychiatrists. This approach ensures that patients are supported by individuals who truly understand their struggles, creating a safe and empathetic space for exchange.

The program was initially tested in a clinical study with 89 patients from different rare disease groups. The results were very promising, showing improvements in mental quality of life, disease acceptance, coping abilities, perceived social support, and reduced helplessness. Encouraged by these findings, we launched the Q.RARE.LI study in 2022 to expand and further evaluate the program.

Looking Ahead: The Q.RARE.LI Study and Future Implementation

Q.RARE.LI is an international study designed to assess the program’s effectiveness across five different healthcare setting. The study not only measures how well the program works but also looks at how it can be successfully integrated into healthcare systems.

Since its launch in summer 2022, more than 250 patients with rare autoimmune liver diseases—Autoimmune Hepatitis (AIH), Primary Sclerosing Cholangitis (PSC), and Primary Biliary Cholangitis (PBC)—were recruited to participate across five countries. These conditions, like many rare diseases, are chronic, progressive, and incurable, with significant impacts on patients’ quality of life. Given their rarity, affected individuals often experience the same struggles seen in the broader rare disease community, making them a suitable population to test the program’s effectiveness.

The study consists of two groups: one receiving the structured peer-counseling intervention in addition to their usual care, and the other continuing with usual care alone. We assess outcomes such as mental health-related quality of life, depression and anxiety severity, perceived social support, helplessness, and disease acceptance at multiple points: before the intervention, immediately after, and three months later. Additionally, implementation outcomes are evaluated through surveys and focus groups involving patients, peer-counselors, and healthcare providers. The goal is to identify potential barriers and facilitators for integrating the program into standard healthcare systems and to develop country-specific implementation strategies.

The results of the Q.RARE.LI study will be available soon and will be shared with the research and patient communities. If successful, this intervention could serve as a scalable model for providing psychosocial support to a wide range of patients with rare diseases beyond those with rare liver conditions. The long-term vision is to expand the program to other rare diseases, ensuring that more patients have access to much-needed emotional and psychological support. If you are interested in learning more about the program and the study, check out the trial registration (ISRCTN15030282) or study protocol (Improving quality of life in patients with rare autoimmune liver diseases by structured peer-delivered support (Q.RARE.LI): study protocol for a transnational effectiveness-implementation hybrid trial | BMC Psychiatry | Full Text) and feel free to reach out!

No one should have to navigate a rare disease alone. Through innovative, accessible, and patient-oriented solutions, we can ensure that every affected individual receives the support they deserve.